Acrux patent triggers milestone payment

By Melissa Trudinger
Friday, 19 November, 2004

Acrux (ASX:ACR) has received a US$250,000 milestone payment from its partner Vivus triggered by the granting of a US patent extending the coverage of its proprietary transdermal drug delivery system.

The patent provides protection for transdermal drug delivery systems consisting of an effective amount of a therapeutic drug, a dermal penetration enhancer and a volatile liquid, with an area of application that becomes touch-dry within 3 minutes of administration.

CEO Igor Gonda said the patent claims provided strategic protection for the product compared to other transdermal drug delivery systems including patches and gels. Acrux has similar patents pending in other international markets.

Related News

Mouth bacteria linked to increased head and neck cancer risk

More than a dozen bacterial species that live in people's mouths have been linked to a...

Life expectancy gains are slowing, study finds

Life expectancy at birth in the world's longest-living populations has increased by an...

Towards safer epilepsy treatment for pregnant women

New research conducted in organoids is expected to provide pregnant women with epilepsy safer...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd